Baxter Travenol
Executive Summary
Firm has completed sale of Flint Labs to Boots for $555 mil. ("The Pink Sheet" Aug. 11, p. 3). Baxter, which may receive additional payments based on future sales of chymopapain, estimates after-tax proceeds at $400 mil.